• Monkeypox Latest news on the simian outbreak in Spain and the world

  • Health Symptoms and details to differentiate monkeypox from other skin lesions

  • Keys Clues to the monkeypox outbreak: less immunity due to not being vaccinated and greater exposure to reservoirs of the virus

Once again, an infectious outbreak puts the importance of the vaccine on the table.

In this case, it is about using the smallpox vaccine to try to contain the outbreak of monkeypox that has sparked alarm in several European countries, including Spain.

"

It is about rescuing vaccines that have some indication for

monkeypox

and in which the machinery would have to be put in to manufacture doses

," explains Amós García Rojas, president of the Spanish Association of Vaccinology.

One of the candidates that

sounds the most,

according to health sources, is the one manufactured by

Bavarian Nordic

.

A Danish company that has the approval of the European Medicines Agency (EMA) to market

Imvanex

, a vaccine against smallpox in humans, but which has data for its use in case of monkey pox infections.

In fact, on Thursday,

Bavarian Nordic

issued a statement mentioning that it

had a pre-sale agreement with a European country.

Sources from the pharmaceutical sector have confirmed to this newspaper that it would be a sale to Germany.

Obstacles of getting a vaccine on demand that is not yet manufactured

In response to an email to this medium, the Danish company, without revealing countries, acknowledges that it has received the order to manufacture doses from several EU states.

But

the problem is the times in which these vaccines would be ready.

The manufacturing technology is not as agile as the one used against Covid, mRNA.

Here it is a vaccine made with

an attenuated modified virus

that cannot multiply rapidly.

From the laboratory they tell this medium that it could take from weeks to months.

This vaccine was approved in 2013 by the EMA and in 2019 by its US counterpart, the FDA.

It has an indication to prevent the disease in adults 18 years of age and older who are at high risk of contracting the disease.

In addition, a little less than 48 hours ago, the company was commissioned by the US Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of Preparedness and Response of the State Department of Health and Human Services,

to manufacture 13 million lyophilized doses in 2023 and 2024

, from the existing bulk vaccine, which had previously been purchased by BARDA.

It is a contract for a first order for 119 million dollars, out of a total of 299 million.

Request for vaccines from the Community of Madrid to Health

In Spain, sources from the sector assure that the Ministry of Defense

has a reserve that could be around the two million doses that were bought due to the Iraq War

and the alleged exposure to biological weapons in 2003. García Rojas recalls that "so they were acquired for this reason so that they could protect the soldiers who were sent to the Persian Gulf."

Enrique Ruiz Escudero, Minister of Health of the Community of Madrid, explained early yesterday that "

the smallpox vaccine could help in prevention

".

From the direction of Public Health, Elena Andradas, comments with EL MUNDO that she has contacted the Spanish Agency for Medicines and Health Products (Aemps) to purchase the vaccine.

"The key is in how the use is proposed, which

will be limited by time

: when the case is detected

in the first four days of contagion, it serves to prevent

the development of the disease, since with the administration of the same it is avoided in a The symptoms are important. If it is done

from day 4 to 14, at most, the clinical symptoms are attenuated

, "says Andradas.

In the

Public Health Commission

held yesterday, Madrid presented its position to the other communities.

And the issue of the alert for this new virus was discussed.

However, some of the autonomies consulted by this newspaper

rule out that any intention has been communicated a priori to make any massive purchase

of vaccines or antivirals.

Andradas explains that they have made a request to Health, to the Aemps, to be able to acquire this vaccine, since it is not marketed in Spain.

In the United Kingdom it has been used in the control of narrow cases.

"

It is the agency that has to acquire batches of this vaccine

, because the one we have in the strategic reserve, about two million, is more reactogenic and is not as suitable," explains the Madrid director.

So far

they have not received an affirmative answer

.

Health argues that "at the moment, the cases are mild and have not required any medication other than those that are available."

Therefore, without ruling out any future action, the acquisition of treatments and vaccines will be made as the situation evolves.

The problem is that "

Madrid, for now, concentrates the most important outbreak,

and the vaccine, as we have explained to the rest of the communities,

would be a useful tool to contain and control the outbreak

," stresses Andradas.

Conforms to The Trust Project criteria

Know more

  • monkey pox

  • Infectious diseases

  • Health

  • THE WORLD

  • United Kingdom

  • Ministry of Defence

  • Coronavirus

  • Germany

  • Europe